Dr. Andrew Keller to Leave Sunshine Biopharma Board at Term End

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced its lead coronavirus drug candidate has entered IND-enabling studies. The company reported nanomolar potency against viral protease, broad-spectrum activity against SARS-CoV-2 variants, and strong oral bioavailability in multiple species. The drug also showed dose-dependent suppression of pulmonary viral replication in vivo. According to the company, the candidate is preferentially enriched in the lungs of mice and rats.

Sunshine Biopharma (NASDAQ:SBFM) announced its lead coronavirus drug candidate has entered IND-enabling studies. The drug showed nanomolar potency against viral protease, broad-spectrum activity against SARS-CoV-2 variants, and significant dose-dependent suppression of pulmonary viral replication in vivo. It also demonstrated strong oral bioavailability and preferential lung enrichment in multiple species.

Sunshine Biopharma (SBFM) advanced its lead coronavirus drug candidate into IND-enabling studies. The PLpro inhibitor showed nanomolar potency, broad in vitro activity against SARS-CoV-2 variants, and dose-dependent viral suppression in infected mice. The company reports high oral bioavailability and lung enrichment in multiple species. Sunshine Biopharma positions this as a differentiated antiviral program with scientific and commercial potential.

Sunshine Biopharma (NASDAQ: SBFM) reported that its K1.1 mRNA therapy showed tumor-suppressing activity in liver cancer models. The company plans to combine it with a cancer vaccine to treat non-small cell lung cancer (NSCLC), aiming to convert 'cold' tumors into 'hot' tumors. The K1.1 mRNA targets a tumor suppressor frequently mutated in lung, pancreatic, and liver cancers.

Sunshine Biopharma (SBFM) reported that its K1.1 mRNA lipid nanoparticle showed tumor-suppressing activity in liver cancer mouse models. The company plans to test the mRNA with a cancer vaccine in non-small cell lung cancer (NSCLC). SBFM's stock declined 6.14% following the announcement, trading at $1.07 with heavy volume.

Sunshine Biopharma (SBFM) received Canadian approval for its generic Enalapril tablets, entering the antihypertensive drug market. The company plans to launch 12 more drugs in 2026 and expects shipments by year-end. The global antihypertensive market is projected to grow to $37.24B by 2034. SBFM shares rose 1.79% in premarket trading.